<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02629575</url>
  </required_header>
  <id_info>
    <org_study_id>AAG-O-H-1408</org_study_id>
    <nct_id>NCT02629575</nct_id>
  </id_info>
  <brief_title>Coroflex ISAR 2000 Registry</brief_title>
  <acronym>ISAR2000</acronym>
  <official_title>Coroflex ISAR 2000 Postmarket Surveillance Non-Interventional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>B. Braun Melsungen AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postmarket surveillance in terms of the safety and efficacy of Sirolimus-eluting Coroflex
      ISAR Stent for the treatment of &quot;real world&quot; patients with de-novo and restenotic lesions
      after stand-alone angioplasty in coronary arteries
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to assess the safety and efficacy of elective deployment of the
      Sirolimus-eluting Coroflex ISAR Stent for the treatment of &quot;real world&quot; de-novo and
      restenotic lesions after stand-alone angioplasty in coronary arteries of 2.0 mm up to 4.0 mm
      in diameter and up to 30 mm in length for procedural success and preservation of vessel
      patency.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>9 Months</target_duration>
  <primary_outcome>
    <measure>clinically driven Target Lesion Revascularization</measure>
    <time_frame>9 months</time_frame>
    <description>re-intervention of the target lesion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events</measure>
    <time_frame>9 months</time_frame>
    <description>MACE=TLR+MI+cardiac/unknown death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction rate</measure>
    <time_frame>9 months</time_frame>
    <description>myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death rate</measure>
    <time_frame>9 months</time_frame>
    <description>cardiac death including death of unknown causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization rate</measure>
    <time_frame>9 months</time_frame>
    <description>TLR=CABG + Re-PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>immediately after stent implantation (within the first 30 minutes)</time_frame>
    <description>Success rate to cross and treat the coronary lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis rates</measure>
    <time_frame>0-9 months</time_frame>
    <description>rates of acute, subacute and 9-month stent thrombosis rates</description>
  </secondary_outcome>
  <enrollment type="Actual">2877</enrollment>
  <condition>Coronary Artery Disease (CAD)</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>stenting with the Coroflex ISAR sirolimus-eluting stent</intervention_name>
    <description>coronary stenting</description>
    <other_name>Coroflex ISAR</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Unselected patients with coronary de-novo and/or restenotic lesions
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients suitable for percutaneous coronary intervention with proof of ischemia

          -  at least 18 years of age

        Exclusion Criteria:

          -  Intolerance to sirolimus and/or probucol

          -  Allergy to components of the coating

          -  Pregnancy and lactation

          -  Complete occlusion of the treatment vessel

          -  Severely calcified stenosis

          -  Cardiogenic shock

          -  Risk of an intraluminal thrombus

          -  Haemorrhagic diathesis or another disorder such as gastro-intestinal ulceration or
             cerebral circulatory disorders which restrict the use of platelet aggregation
             inhibitor therapy and anti-coagulation therapy

          -  Surgery shortly after myocardial infarction with indications of thrombus or poor
             coronary flow behavior

          -  Severe allergy to contrast media

          -  Lesions which are untreatable with PTCA or other interventional techniques

          -  Patients with an ejection fraction of &lt; 30 %

          -  Vascular reference diameter &lt; 2.00 mm

          -  Treatment of the left stem (first section of the left coronary artery)

          -  Indication for a bypass surgery

          -  Contraindication for whichever accompanying medication is necessary
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florian Krackhardt, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité Virchow Unversity Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité University Hospital</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusat Perubatan Universiti Malaya</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Malaysia</country>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Massberg S, Byrne RA, Kastrati A, Schulz S, Pache J, Hausleiter J, Ibrahim T, Fusaro M, Ott I, Schömig A, Laugwitz KL, Mehilli J; Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting Versus Zotarolimus- Eluting Stents (ISAR-TEST 5) Investigators. Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial. Circulation. 2011 Aug 2;124(5):624-32. doi: 10.1161/CIRCULATIONAHA.111.026732. Epub 2011 Jul 18.</citation>
    <PMID>21768546</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2015</study_first_submitted>
  <study_first_submitted_qc>December 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2015</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

